03:47:22 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaLarge Cap Helsinki
IndustriLäkemedel & Handel
Orion är en finsk koncern med verksamhet inom läkemedelsindustrin. Bolaget bedriver idag forskning och utveckling av humana – och veterinära läkemedel, där störst fokus innehas inom sjukdomar som drabbar nervsystemet, samt onkologi och luftvägssjukdomar. Idag återfinns bolagets produkter på global nivå, med störst närvaro inom Skandinavien och övriga Europa. Bolagets huvudkontor ligger i Espoo.


2021-10-20 Kvartalsrapport 2021-Q3
2021-07-19 Kvartalsrapport 2021-Q2
2021-04-27 Kvartalsrapport 2021-Q1
2021-03-25 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-10-21 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-05-07 Ordinarie utdelning ORNBV 1.50 EUR
2020-05-07 Ordinarie utdelning ORNAV 1.50 EUR
2020-05-06 Årsstämma 2020
2020-04-28 Kvartalsrapport 2020-Q1
2020-03-26 Ordinarie utdelning ORNBV 1.50 EUR
2020-02-05 Bokslutskommuniké 2019
2019-10-23 Kvartalsrapport 2019-Q3
2019-07-17 Kvartalsrapport 2019-Q2
2019-04-25 Kvartalsrapport 2019-Q1
2019-03-27 Ordinarie utdelning ORNAV 1.50 EUR
2019-03-27 Ordinarie utdelning ORNBV 1.50 EUR
2019-03-26 Årsstämma 2019
2019-02-06 Bokslutskommuniké 2018
2018-10-24 Kvartalsrapport 2018-Q3
2018-07-18 Kvartalsrapport 2018-Q2
2018-04-24 Kvartalsrapport 2018-Q1
2018-03-21 Ordinarie utdelning ORNAV 1.45 EUR
2018-03-21 Ordinarie utdelning ORNBV 1.45 EUR
2018-03-20 Årsstämma 2018
2018-02-07 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-07-19 Kvartalsrapport 2017-Q2
2017-05-18 Kapitalmarknadsdag 2017
2017-04-26 Kvartalsrapport 2017-Q1
2017-03-23 Ordinarie utdelning ORNBV 1.35 EUR
2017-03-23 Bonusutdelning ORNAV 0.2
2017-03-23 Ordinarie utdelning ORNAV 1.35 EUR
2017-03-23 Bonusutdelning ORNBV 0.2
2017-03-22 Årsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-10-25 Kvartalsrapport 2016-Q3
2016-07-19 Kvartalsrapport 2016-Q2
2016-04-27 Kvartalsrapport 2016-Q1
2016-03-23 Ordinarie utdelning ORNAV 1.30 EUR
2016-03-23 Ordinarie utdelning ORNBV 1.30 EUR
2016-03-22 Årsstämma 2016
2016-02-02 Bokslutskommuniké 2015
2015-10-27 Kvartalsrapport 2015-Q3
2015-07-28 Kvartalsrapport 2015-Q2
2015-05-26 Kapitalmarknadsdag 2015
2015-04-29 Kvartalsrapport 2015-Q1
2015-03-25 Ordinarie utdelning ORNAV 1.30 EUR
2015-03-25 Ordinarie utdelning ORNBV 1.30 EUR
2015-03-24 Årsstämma 2015
2015-02-04 Bokslutskommuniké 2014
2014-03-26 Ordinarie utdelning
2014-03-26 Ordinarie utdelning ORNBV 1.25 EUR
2013-03-20 Ordinarie utdelning
2013-03-20 Ordinarie utdelning ORNBV 1.30 EUR
2012-03-21 Bonusutdelning ORNBV 0.12
2012-03-21 Ordinarie utdelning ORNBV 1.30 EUR
2012-03-21 Ordinarie utdelning
2012-03-21 Bonusutdelning
2011-04-01 Bonusutdelning ORNBV 0.06
2011-04-01 Ordinarie utdelning ORNAV 1.20 EUR
2011-04-01 Bonusutdelning ORNAV 0.06
2011-04-01 Ordinarie utdelning ORNBV 1.20 EUR
2010-03-25 Ordinarie utdelning
2010-03-25 Ordinarie utdelning ORNBV 1.00 EUR
2010-03-25 Bonusutdelning ORNBV 0.1
2010-03-25 Bonusutdelning
2009-03-24 Ordinarie utdelning
2009-03-24 Ordinarie utdelning ORNBV 0.95 EUR
2008-03-26 Ordinarie utdelning ORNBV 1.00 EUR
2007-04-03 Ordinarie utdelning ORNBV 1.00 EUR
2007-04-03 Ordinarie utdelning
2006-03-22 Ordinarie utdelning ORNBV 0.85 EUR
2005-03-22 Ordinarie utdelning
2005-03-22 Ordinarie utdelning ORNBV 0.55 EUR
2004-09-15 Bonusutdelning
2004-09-15 Bonusutdelning ORNBV 2.14
2004-03-23 Ordinarie utdelning
2004-03-23 Ordinarie utdelning ORNBV 1.60 EUR
2003-12-12 Bonusutdelning ORNBV 1.5
2003-12-12 Bonusutdelning
2003-03-23 Ordinarie utdelning
2003-03-23 Ordinarie utdelning ORNBV 0.93 EUR
2002-04-16 Ordinarie utdelning ORNBV 1.10 EUR
2002-04-16 Ordinarie utdelning
2001-03-30 Ordinarie utdelning
2001-03-30 Ordinarie utdelning ORNBV 1.20 EUR
2000-03-31 Ordinarie utdelning ORNBV 1.18 EUR
2000-03-31 Ordinarie utdelning
1999-07-28 Bonusutdelning
1999-07-28 Bonusutdelning
1999-04-09 Ordinarie utdelning
1999-04-09 Ordinarie utdelning
1998-04-21 Ordinarie utdelning
1998-04-21 Ordinarie utdelning
1997-04-22 Ordinarie utdelning
1997-04-22 Ordinarie utdelning
1996-04-23 Ordinarie utdelning
1996-04-23 Ordinarie utdelning
2020-11-10 07:30:00

ORION CORPORATION    PRESS RELEASE    10 NOVEMBER 2020 at  8.30 a.m. EET             



Orion invests EUR 17 million in its production plants in Turku


Orion upgrades the operations of its pharmaceutical plant in Turku by investing in a new cancer drug packaging line and by expanding its cream production department. The company is also building a new pure water system and district heating centre for the plant. The investments are due to the growing demand of the products, and their total value is EUR 17 million.


The Orion plant in Turku produces cytostatic cancer drugs, which are sold globally. Through the investments, the cancer drug department at the plant will be upgraded by adding a blister packaging line to the production chain, alongside the existing bottle lines.


The production volumes in the cream and ointment department have also increased steadily over the years. Now Orion invests in expanding and modernising the facilities. The department manufactures basic creams and medical creams. In addition, especially the veterinary ointments and liquid medicines are made for international markets. The production volumes of the veterinary creams and liquid medicines are expected to increase due to new product launches in the near future.


“The main reason for the investments is to enable growth as the demand for our products is increasing. We need more space and capacity, and technologies will also be replaced with newer ones. The new blister packaging meets both the wishes of the patients and the future requirements of pharmaceutical authorities around the world,” says Liisa Hurme, Senior Vice President, Global Operations at Orion.


The new district heating centre is part of Orion’s energy programme. The programme aims for significant cost savings in energy consumption, as well as a reduction in greenhouse gas emissions by 75% by the year 2025.


All the investment projects are already in progress and the construction work begins in November. The contractors implementing the work will have more than 50 people working full time for the projects. Orion has around 700 employees in Turku, of whom more than 400 work in production.


Orion manufactures all of its patented proprietary drugs and also most of their pharmaceutical ingredients in Finland. The company has made substantial investments during the last few years.


“Over the past five years, Orion has invested around EUR 160 million in its production plants in Finland,” Liisa Hurme says. Orion was among the ten biggest payers of corporation tax on operating profit in Finland by paying approximately EUR 50 million corporation tax in 2019.





Further information:

Contact person for the media:

Liisa Hurme

SVP, Global Operations, Orion Corporation

Tel. +358 50 966 2874


Terhi Ormio

VP, Communications, Orion Corporation

Tel. +358 50 966 4646






Orion Corporation


Orionintie 1A, FI-02200 Espoo, Finland



Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.